Contribution of MEK/MAPK and PI3‐K signaling pathway to the malignant behavior of Ewing's sarcoma cells: Therapeutic prospects

Insulin‐like growth factor receptor I (IGF‐I)‐mediated circuit is a major autocrine loop for Ewing's sarcoma (ES) cells and appears to be particularly important in the pathogenesis of this tumor. In this study, we analyzed the contribution of the 2 major pathways of the intracellular IGF‐IR signaling cascade to the overall effects elicited by IGF‐I in ES. Both the mitogen‐activated protein kinase (MAPK) and phosphatidylinositol‐3‐kinase (PI3‐K) signaling pathways appeared to be constitutively activated in ES, likely due to the presence of the IGF‐IR‐mediated autocrine loop. We demonstrated that both MEK/MAPK (PD98059 or U0126) and PI3‐K inhibitors (LY294002) profoundly impaired ES cell growth in monolayer and soft agar basal conditions. Both PD98059 and LY294002 inhibited ES cell cycle progression by inducing G1 blockage, whereas only LY294002 significantly affected the survival of ES cells. Exogenous IGF‐I completely reverted LY294002‐induced growth inhibition by abrogating antiproliferative and proapoptotic effects of the PI3‐K inhibitor. By contrast, IGF‐I could not rescue cells from growth inhibition induced by PD98059. MEK/MAPK blockade also significantly reduced the migratory ability of ES cells, both in basal and IGF‐I‐induced conditions, and increased chemosensitivity to doxorubicin, a leader drug in the treatment of ES patients. Our findings therefore identify MAPK pathway as a promising target for pharmacologic intervention in ES. © 2003 Wiley‐Liss, Inc.

[1]  D. Yee,et al.  Insulin-like growth factor I expression by tumors of neuroectodermal origin with the t(11;22) chromosomal translocation. A potential autocrine growth factor. , 1990, The Journal of clinical investigation.

[2]  J. Toretsky,et al.  Phosphoinositide 3-hydroxide kinase blockade enhances apoptosis in the Ewing's sarcoma family of tumors. , 1999, Cancer research.

[3]  L. Wang,et al.  Inhibition of mitogen-activated protein kinase kinase selectively inhibits cell proliferation in human breast cancer cells displaying enhanced insulin-like growth factor I-mediated mitogen-activated protein kinase activation. , 2000, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[4]  F. Peruzzi,et al.  Regulation of Id Gene Expression by Type I Insulin-Like Growth Factor: Roles of STAT3 and the Tyrosine 950 Residue of the Receptor , 2001, Molecular and Cellular Biology.

[5]  P. Lollini,et al.  Blockage of insulin-like growth factor-I receptor inhibits the growth of Ewing's sarcoma in athymic mice. , 1998, Cancer research.

[6]  P. Lollini,et al.  Insulin-like growth factor I receptor-mediated circuit in Ewing's sarcoma/peripheral neuroectodermal tumor: a possible therapeutic target. , 1996, Cancer research.

[7]  D. Leroith,et al.  The Insulin-like Growth Factor-I Receptor Is Required for EWS/FLI-1 Transformation of Fibroblasts* , 1997, The Journal of Biological Chemistry.

[8]  S. Aaronson,et al.  Basis for the acquisition of malignant potential by mouse cells cultivated in vitro. , 1968, Science.

[9]  B. Calabretta,et al.  Multiple Signaling Pathways of the Insulin-Like Growth Factor 1 Receptor in Protection from Apoptosis , 1999, Molecular and Cellular Biology.

[10]  P. Lollini,et al.  Effectiveness of insulin-like growth factor I receptor antisense strategy against Ewing's sarcoma cells , 2002, Cancer Gene Therapy.

[11]  M. Karas,et al.  Insulin-like Growth Factor-I (IGF-I) Receptor Activation Rescues UV-damaged Cells through a p38 Signaling Pathway , 2001, The Journal of Biological Chemistry.

[12]  D. Leroith Insulin-like growth factor I receptor signaling--overlapping or redundant pathways? , 2000, Endocrinology.

[13]  L. Wang,et al.  Stat5 is a physiological substrate of the insulin receptor. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[14]  D. Leroith,et al.  Mitogen-activated protein kinase and phosphatidylinositol 3-kinase pathways are not sufficient for insulin-like growth factor I-induced mitogenesis and tumorigenesis. , 1997, Endocrinology.

[15]  Philip R. Cohen,et al.  SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin‐1 , 1995, FEBS letters.

[16]  J. Sebolt-Leopold Development of anticancer drugs targeting the MAP kinase pathway , 2000, Oncogene.

[17]  S. Aaronson,et al.  Basis for the Acquaisition of Malignant Potential by Mouse Cells Cultivated in vitro , 1968, Science.

[18]  K Y Hui,et al.  A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). , 1994, The Journal of biological chemistry.

[19]  O. Larsson,et al.  A link between basic fibroblast growth factor (bFGF) and EWS/FLI-1 in Ewing's sarcoma cells , 2000, Oncogene.

[20]  G. Romano,et al.  Dissociation between resistance to apoptosis and the transformed phenotype in IGF‐I receptor signaling , 1999, Journal of cellular biochemistry.

[21]  P. Lollini,et al.  Inhibition of insulin-like growth factor I receptor increases the antitumor activity of doxorubicin and vincristine against Ewing's sarcoma cells. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[22]  D. Andrews,et al.  Results of a pilot study involving the use of an antisense oligodeoxynucleotide directed against the insulin-like growth factor type I receptor in malignant astrocytomas. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  C. Klopp,et al.  Application of balloon technique in detection of cancer , 1953, Cancer.

[24]  Philip R. Cohen,et al.  PD 098059 Is a Specific Inhibitor of the Activation of Mitogen-activated Protein Kinase Kinase in Vitro and in Vivo(*) , 1995, The Journal of Biological Chemistry.

[25]  C. Sawyers,et al.  The phosphatidylinositol 3-Kinase–AKT pathway in human cancer , 2002, Nature Reviews Cancer.

[26]  D. Levy,et al.  Mechanism of STAT3 Activation by Insulin-like Growth Factor I Receptor* , 2000, The Journal of Biological Chemistry.

[27]  W. Winkelmann,et al.  Ewing's tumors with primary lung metastases: survival analysis of 114 (European Intergroup) Cooperative Ewing's Sarcoma Studies patients. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  D. Leroith,et al.  Insulin-like Growth Factor I Induces MDM2-dependent Degradation of p53 via the p38 MAPK Pathway in Response to DNA Damage* , 2002, The Journal of Biological Chemistry.

[29]  E. Feldman,et al.  GTPases and phosphatidylinositol 3-kinase are critical for insulin-like growth factor-I-mediated Schwann cell motility. , 2000, The Journal of biological chemistry.

[30]  R. Baserga The contradictions of the insulin-like growth factor 1 receptor , 2000, Oncogene.

[31]  D. Leroith Editorial: Insulin-Like Growth Factor I Receptor Signaling-Overlapping or Redundant Pathways? , 2000, Endocrinology.

[32]  J. Blenis,et al.  Molecular mechanisms mediating mammalian mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK cell survival signals. , 2001, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[33]  M. Rubini,et al.  The IGF-I receptor in cell growth, transformation and apoptosis. , 1997, Biochimica et biophysica acta.

[34]  H. Kovar,et al.  The Ewing family of tumors and the search for the Achilles' heel. , 1999, Current opinion in oncology.

[35]  M. Campanacci Bone and Soft Tissue Tumors , 1999, Springer Vienna.

[36]  R. Souhami,et al.  Ifosfamide-containing chemotherapy in Ewing's sarcoma: The Second United Kingdom Children's Cancer Study Group and the Medical Research Council Ewing's Tumor Study. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  P. Sorensen,et al.  Anchorage-independent multi-cellular spheroids as an in vitro model of growth signaling in Ewing tumors , 2002, Oncogene.

[38]  P. Lollini,et al.  Expression of an IGF‐I receptor dominant negative mutant induces apoptosis, inhibits tumorigenesis and enhances chemosensitivity in Ewing's sarcoma cells , 2002, International journal of cancer.

[39]  D. Leroith,et al.  Insulin-like Growth Factor 1 Inhibits Apoptosis Using the Phosphatidylinositol 3′-Kinase and Mitogen-activated Protein Kinase Pathways* , 1997, The Journal of Biological Chemistry.

[40]  R. Ilaria,et al.  Interference with the constitutive activation of ERK1 and ERK2 impairs EWS/FLI-1-dependent transformation , 2000, Oncogene.

[41]  J. Oh,et al.  Up-regulation of urokinase-type plasminogen activator by insulin-like growth factor-I depends upon phosphatidylinositol-3 kinase and mitogen-activated protein kinase kinase. , 2001, Cancer research.

[42]  F. Hobbs,et al.  Identification of a Novel Inhibitor of Mitogen-activated Protein Kinase Kinase* , 1998, The Journal of Biological Chemistry.

[43]  L. Flechner,et al.  Protein Kinase C-δ Is an Important Signaling Molecule in Insulin-Like Growth Factor I Receptor-Mediated Cell Transformation , 1998, Molecular and Cellular Biology.

[44]  T. Triche,et al.  The Ewing family of tumors--a subgroup of small-round-cell tumors defined by specific chimeric transcripts. , 1994, The New England journal of medicine.

[45]  P. Picci,et al.  The expression of ccn3(nov) gene in musculoskeletal tumors. , 2002, The American journal of pathology.

[46]  R. Baserga,et al.  Regulation of Id2 Gene Expression by the Insulin-like Growth Factor I Receptor Requires Signaling by Phosphatidylinositol 3-Kinase* , 2001, The Journal of Biological Chemistry.

[47]  K. Nguyen,et al.  Differential requirements of the MAP kinase and PI3 kinase signaling pathways in Src- versus insulin and IGF-1 receptors-induced growth and transformation of rat intestinal epithelial cells , 2000, Oncogene.

[48]  S. Ferrari,et al.  Neoadjuvant chemotherapy for Ewing's sarcoma of bone , 1998, Cancer.

[49]  J. V. van Leeuwen,et al.  Regulation of Osteocalcin Production and Bone Resorption by 1,25‐Dihydroxyvitamin D3 in Mouse Long Bones: Interaction with the Bone‐Derived Growth Factors TGF‐β and IGF‐I , 1998, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[50]  T. MacDonald,et al.  The Ewing tumor family of peripheral primitive neuroectodermal tumors expresses human gastrin-releasing peptide. , 1998, Cancer research.

[51]  M. Ladanyi,et al.  Association of EWS-FLI1 type 1 fusion with lower proliferative rate in Ewing's sarcoma. , 2000, The American journal of pathology.